Literature DB >> 16573774

Reports of "satisfactory relief" by IBS patients receiving usual medical care are confounded by baseline symptom severity and do not accurately reflect symptom improvement.

William E Whitehead1, Olafur S Palsson, Rona L Levy, Andrew D Feld, Michael VonKorff, Marsha Turner.   

Abstract

BACKGROUND: Treatment trials for irritable bowel syndrome (IBS) usually define a responder as a patient who reports satisfactory relief or adequate relief of symptoms at the end of the trial. However, these measures have not been adequately validated. AIMS: (1) Compare a binary satisfactory relief measure to alternative ways of defining a treatment responder. (2) Determine whether baseline IBS symptom severity or psychological distress influence the sensitivity of these outcome measures.
METHODS: A total of 350 patients (81% females, average age 50 yr) who had a medical diagnosis of IBS and satisfied Rome II criteria, were recruited from Group Health Cooperative of Puget Sound. At baseline the Irritable Bowel Severity Scale (IBSS) was used to assess symptom severity and to classify patients as mild, moderate, or severe. Psychological distress and IBS-specific quality of life (IBS-QOL) were also assessed. After 6 months treatment with standard medical care, IBSS and IBS-QOL were reassessed, and patients were asked whether they had experienced satisfactory relief and whether they were somewhat or markedly better.
RESULTS: Initial severity of IBS significantly affected the proportion who reported satisfactory relief (mild, 72%; moderate, 53%; severe, 44%) and the proportion who were somewhat or markedly better (mild, 62%; moderate, 44%; severe, 38%), but did not affect the proportion with a 50% reduction in symptoms (mild, 26%; moderate, 25%; severe, 23%). Although mild patients were the most likely to report satisfactory relief, they showed no average decrease in symptom severity or improvement in IBS-QOL. Conversely, severe patients, who were the least likely to report satisfactory relief, had the largest reductions in IBS symptom severity and the largest improvements in IBS-QOL. Psychological distress had no significant effect on the responder rate after adjusting for IBS symptom severity.
CONCLUSIONS: These data from a descriptive study suggest that satisfactory relief is confounded with initial IBS symptom severity and is poorly correlated with the amount of symptom improvement. Confirmation of these findings in a clinical trial is needed.

Entities:  

Mesh:

Year:  2006        PMID: 16573774     DOI: 10.1111/j.1572-0241.2006.00535.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  23 in total

Review 1.  Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles.

Authors:  Michael Camilleri; Lin Chang
Journal:  Gastroenterology       Date:  2008-10-09       Impact factor: 22.682

2.  Psychometric evaluation of patient-reported outcomes in irritable bowel syndrome randomized controlled trials: a Rome Foundation report.

Authors:  Brennan Spiegel; Michael Camilleri; Roger Bolus; Viola Andresen; William D Chey; Sheri Fehnel; Allen Mangel; Nicholas J Talley; William E Whitehead
Journal:  Gastroenterology       Date:  2009-08-23       Impact factor: 22.682

Review 3.  New treatments for IBS.

Authors:  Magnus Halland; Nicholas J Talley
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-11-13       Impact factor: 46.802

4.  Factors affecting response to proton pump inhibitor therapy in patients with gastroesophageal reflux disease: a multicenter prospective observational study.

Authors:  Nobuyuki Matsuhashi; Mineo Kudo; Norimasa Yoshida; Kazunari Murakami; Mototsugu Kato; Tsuyoshi Sanuki; Atsushi Oshio; Takashi Joh; Kazuhide Higuchi; Ken Haruma; Koji Nakada
Journal:  J Gastroenterol       Date:  2015-04-08       Impact factor: 7.527

5.  Editorial: is adequate relief fatally flawed or adequate as an end point in irritable bowel syndrome?

Authors:  Michael Camilleri
Journal:  Am J Gastroenterol       Date:  2009-03-17       Impact factor: 10.864

6.  Adequate relief in a treatment trial with IBS patients: a prospective assessment.

Authors:  Maria C F Passos; Anthony J Lembo; Lisa A Conboy; Ted J Kaptchuk; John M Kelly; Mary T Quilty; Catherine E Kerr; Eric E Jacobson; Rong Hu; Elizabeth Friedlander; Douglas A Drossman
Journal:  Am J Gastroenterol       Date:  2009-03-17       Impact factor: 10.864

7.  The effect of tegaserod on symptoms and quality of life in korean women with irritable bowel syndrome with constipation.

Authors:  Yong Sung Kim; Suck Chei Choi; Jae Myung Park; Chang Hwan Choi; Dong Ho Lee; Hee Jung Son; In Kyung Sung; Jeong Jo Jeong; Joon Seong Lee; Ki Nam Shim; Kwang Jae Lee; Su Jin Hong; Myung-Gyu Choi
Journal:  J Neurogastroenterol Motil       Date:  2010-01-31       Impact factor: 4.924

8.  Reply.

Authors:  Yong Sung Kim; Suck Chei Choi
Journal:  J Neurogastroenterol Motil       Date:  2010-04-28       Impact factor: 4.924

9.  A novel technique for bedside anorectal manometry in humans.

Authors:  A E Bharucha; R Stroetz; K Feuerhak; L A Szarka; A R Zinsmeister
Journal:  Neurogastroenterol Motil       Date:  2015-07-30       Impact factor: 3.598

10.  Mindfulness for irritable bowel syndrome: protocol development for a controlled clinical trial.

Authors:  Susan A Gaylord; William E Whitehead; Rebecca S Coble; Keturah R Faurot; Olafur S Palsson; Eric L Garland; William Frey; John Douglas Mann
Journal:  BMC Complement Altern Med       Date:  2009-07-28       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.